DOCSLIB.ORG

Covid-19 Retractions Raise Concerns About Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Covid-19 Retractions Raise Concerns About Data News in focus in South America, says Carlos Chaccour of the Barcelona Institute for Global Health in Spain, COVID-19 RETRACTIONS who is running a clinical trial of ivermectin and had raised questions about the preprint’s data. RAISE CONCERNS ABOUT Researchers testing hydroxychloroquine in clinical trials are worried that the Lancet find- DATA OVERSIGHT ings might make it harder for them to complete their research, despite the fact that the paper Studies relied on health-record analyses from firm has been retracted. “We’re hearing that people just aren’t interested in hydroxychloroquine,” that declined to share its raw data for an audit. says David Smith, an infectious-disease special- ist at the University of California, San Diego, By Heidi Ledford and who is helping to run a trial of the drug in people Richard Van Noorden with COVID-19 who have not been hospitalized. Most data on hydroxychloroquine in wo weeks after a high-profile paper COVID-19 have come from in vitro studies in The Lancet1 reported that the anti- or small clinical trials. On 5 June, however, malarial drug hydroxychloroquine researchers working on a large randomized might be dangerous to people with UK trial called RECOVERY announced that their COVID-19, three of its four authors data on more than 4,600 hospitalized people Tretracted the work because they were unable indicated that hydroxychloroquine didn’t to independently verify their data set, a reduce the risk of death, and that they were large proprietary collection of electronic stopping that arm of the trial. health records analysed by the US company It is not uncommon for studies that use Surgisphere. large data sets to be published without exter- On the same day, 4 June, the researchers nal scrutiny of the raw data, says Smith. But and other co-authors retracted a paper2 in an exception is when the paper is expected to The New England Journal of Medicine, for the have particularly high impact. In the Lancet same reason. That study, published a month study, he says, it seems that extra-careful NARINDER NANU/AFP/GETTY ago, had looked at the impact of certain heart Hydroxychloroquine, an antimalarial drug. review was skipped. “We are desperate for medications on people with COVID-19, and knowledge, and maybe we’re skipping over found no safety concerns. Sapan Desai, the founder of Surgisphere some of our tried-and-true checks,” he says. Scientists say the affair raises serious and a co-author of the studies, declined to questions about how researchers and jour- comment to Nature on the retractions and on Ivermectin effect nals evaluate the data underlying papers concerns about the quality of the data behind Surgisphere’s ivermectin preprint might that they publish, and might complicate the the studies. have a longer life. The Peruvian government effort to trial drugs during the coronavirus After the Lancet study appeared, some included the drug in its national treatment pandemic. “This whole event is catastrophic regulators paused enrolment in clinical trials guidelines a few days after a white paper cited — it is problematic for the journals involved, it of hydroxychloroquine as a treatment for the SSRN preprint, Chaccour says. A week after is problematic for the integrity of science, it is COVID-19. The drug, which is cheap and easy that, Bolivia added ivermectin to its treatment problematic for medicine and it is problematic to administer, has been widely endorsed dur- guidelines, citing the situation in Peru. for the notion of clinical trials and evidence ing the pandemic, despite scant evidence of its Since Chaccour gave a talk about ivermectin generation,” says Ian Kerridge, a bioethicist at to the Peruvian Academy of Sciences, he says, the University of Sydney, Australia. “I no longer have confidence people regularly text him to say that they have Both papers relied on analysis of proprietary an infected family member and can get formula- data from electronic health records on tens in the origination and tions of ivermectin intended for use in animals, of thousands of people that were apparently veracity of the data, nor the not people. “They send me a photo of a veteri- gathered from hundreds of hospitals around findings they have led to.” nary formulation and ask me, ‘Would you mind the world by Surgisphere, which is based in telling me what dose we should use?’” he says. Chicago, Illinois. But even after critics raised “It is broadly available and people are broadly questions about the studies, the firm did not effectiveness. Some of the halted trials, includ- desperate and this could lead to misuse.” make its raw data available to third-party ing one led by the World Health Organization, Because the preprint was not published in auditors for validation. According to the are starting up again. a journal, there is no retraction mechanism Lancet retraction notice, Surgisphere was A third study authored by Desai, Mehra to limit its long reach, Chaccour worries. concerned that transferring the data would and others, which used Surgisphere data “Who retracts this ivermectin ghost in Latin violate “client agreements and confidentiality and reported finding a large reduction in America?” he says. “There’s no high-profile requirements”. COVID-19 mortality when patients were journal saying this was wrong.” “Since we do not have the ability to verify given the anti-parasitic drug ivermectin, the primary data or primary data source, I no has disappeared from the social-sciences Additional reporting by Smriti Mallapaty and longer have confidence in the origination and preprint server SSRN, where it was posted in David Cyranoski veracity of the data, nor the findings they have April. Mehra told Nature that he removed it led to,” said Mandeep Mehra, a cardiologist because he “did not feel it was ready for peer 1. Mehra, M. R., Desai, S. S., Ruschitzka, F. & Patel, A. N. Lancet https://doi.org/10.1016/S0140-6736(20)31180-6 at Brigham and Women’s Hospital in Boston, review”. It was not published in a peer-re- (2020). Massachusetts, who was the lead author of viewed journal, but has nonetheless contrib- 2. Mehra, M. R., Desai, S. S., Kuy S., Henry, T. D. & Patel, A. N. both studies. uted to a surge in the popularity of ivermectin N. Engl. J. Med. https://10.1056/NEJMoa2007621 (2020). 160 | Nature | Vol 582 | 11 June 2020 ©2020 Spri nger Nature Li mited. All ri ghts reserved. .
Load more

Recommended publications
  • Daily Evidence Digest 4 June 2020
    Daily evidence digest 4 June 2020 The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation. Physical distancing, face masks, heart failure, research quality Peer reviewed journals featured: A systematic review on physical distancing, face masks, and eye protection to prevent person- to-person transmission here A rapid review on dysphagia assessment as a potential aerosol generating procedure here Impact of COVID‐19 pandemic on STEMI in a non‐COVID‐19 epicentre here A brief report on eating disorders during the COVID‐19 pandemic in Australia here Data on the impact of COVID‐19 on heart failure hospitalisation and management here A survey on the use of telemedicine for head and neck ambulatory visits here Racial and ethnic disparities in long-term services here Tele-palliative medicine volunteers in New York here A commentary on the physical, mental, and social issues and challenges faced by unpaid home care providers here A BMJ feature article on how NHS mental health services are adapting to provide care here A small case report on three COVID-19 patients with encephalopathy and encephalitis here Two ‘expressions of concern’ about the quality of information and reliability of conclusions of a retrospective study in NEJM on ACE inhibitors and ARBs here and a multinational registry analysis of hydroxychloroquine for treatment of COVID-19 in the Lancet here Letters and correspondence Self-risk assessment for patients with rheumatic disease
    [Show full text]
  • Misinformation in the COVID-19
    Editor’s column J NeuroIntervent Surg: first published as 10.1136/neurintsurg-2020-016683 on 14 August 2020. Downloaded from acute strokes, predominantly affecting Misinformation in the COVID-19 era otherwise healthy people <50 years of age.12 13 Endothelial dysfunction, hyper- Gabor Toth ,1 Alejandro M Spiotta,2 Joshua A Hirsch ,3 coaguability, ACE2 receptor variability, 4 upregulated inflammatory response and David Fiorella resultant thrombotic events have all been hypothesized as possible causes for The COVID-19 pandemic has taken a toll of primary data sources”.7 Medical jour- these unusual cases, but definitive data on humankind that is remarkable for a nals not properly “vetting” and eventually are currently lacking. One of the alter- disease in modern times. As of late June publishing high-impact articles that turn native explanations may be that some 2020, almost 500 000 people have died of out to be based on unverified data can of the “healthy” patients actually have the disease worldwide, including more misguide providers as well as the public. underlying but previously unknown than 120 000 in the USA, with estimates of Information on the disease that was previ- risk factors contributing to the vascular infected individuals approaching ously restricted to medical professionals is events. It is also possible that younger 10 million.1 The numbers of infected and now available to the broad public by the patients are more likely to have asymp- deceased patients will continue to rise. swipe of a screen, just like any other news- tomatic COVID-19 infection, and in In these times of considerable uncer- reel.
    [Show full text]
  • Frauds in Scientific Research and How to Possibly Overcome Them Erik Boetto,1 Davide Golinelli ‍ ,1 Gherardo Carullo,2 Maria Pia Fantini1
    Current controversy J Med Ethics: first published as 10.1136/medethics-2020-106639 on 6 October 2020. Downloaded from Frauds in scientific research and how to possibly overcome them Erik Boetto,1 Davide Golinelli ,1 Gherardo Carullo,2 Maria Pia Fantini1 1Department of Biomedical and ABSTRACT their activities, while also evaluating the quality of Neuromotor Sciences, University Frauds and misconduct have been common in the history the scientific evidence provided. of Bologna, Bologna, Italy 2Department of Italian and of science. Recent events connected to the COVID-19 COVID-19 pandemic is giving us a glimpse of Supranational Public Law, pandemic have highlighted how the risks and consequences how scientific research might evolve in the future: University of Milan, Milano, of this are no longer acceptable. Two papers, addressing researchers want to share their work in a quick, Lombardia, Italy the treatment of COVID-19, have been published in two of open- access fashion, in order to receive immediate the most prestigious medical journals; the authors declared feedback and recognition by their peers. Preprint Correspondence to to have analysed electronic health records from a private servers allow them to do so, as shown by their Dr Davide Golinelli, Department of Biomedical and Neuromotor corporation, which apparently collected data of tens of increased popularity: almost 4000 COVID-19 Sciences, University of Bologna, thousands of patients, coming from hundreds of hospitals. papers have been submitted to medRxiv alone as Bologna 40126, Italy; Both papers have been retracted a few weeks later. When of June 2020.1 davide. golinelli@ unibo. it such events happen, the confidence of the population While this ‘torrent of preprints’ surely contrib- in scientific research is likely to be weakened.
    [Show full text]
  • Church Closures, Lancet, Rioters, Planned Parenthood …And Thomas More
    Church Closures, Lancet, Rioters, Planned Parenthood …and Thomas More Click here to watch the video. A couple of weeks ago, I uploaded a video about the coronavirus lockdowns in California, especially with regard to the closure of churches. Since that time, many governors across the nation have issued new rules dictating exactly how many people are allowed to attend church at any given time. In all of California, for example, churches can only open their doors to 25% of their total capacity or 100 people, whichever is less. New Jersey churches can only open to 25 people. Period. In Minnesota, all religious books must be removed from churches, even though the CDC recently came out with new guidance saying the threat of spreading the virus through surface contact is remote. And until a few days ago, religious services in New York were limited to 10 people. A church in Southern California sued the governor in federal court to lift California’s restrictive order. When they lost at the Ninth Circuit Court of Appeals, they petitioned the Supreme Court to review their case. And, thanks to Chief Justice John Roberts, the church lost. It should be noted that the church is located in San Diego county—a county of 3.3 million people that has seen a total of 296 COVID deaths to date. Nevertheless, Justice Roberts gave short shrift to the First Amendment, finding that “Our Constitution entrusts the safety and the health of the people to the politically accountable officials of the States to guard and protect.” In other words, the highly questionable power of governors to lock healthy people in their homes for months on end trumps the express religious rights found in the Constitution.
    [Show full text]
  • Stocks Cap Best Week Since July
    P2JW284000-8-A00100-17FFFF5178F What the Are Yo u Ready for Pandemic Has Fashion Again? Taught Us OFF DUTY About Science REVIEW WSJ THE WALL STREETJOURNAL WEEKEND ******** SATURDAY/SUNDAY,OCTOBER 10 -11, 2020 ~VOL. CCLXXVI NO.86 WSJ.com HHHH $5.00 Hurricane Delta Lashes Storm-Scarred Louisiana Coast Boosted What’s News Offer World-Wide Kindles he White House sub- Hope for Tstantially increased its offer to Democrats on a coronavirus-relief pack- Stimulus age, further closing the gap between the parties in the on-again, off-again ef- White House narrows fort to pass new aid for households and businesses gap with Democrats, before the election. A1 but a deal before Painful social lockdowns election faces hurdles in Europe and some Ameri- canstateshelped blunt the The White House substan- coronavirus.Now,amid afit- tially increased itsoffer to fulreopening,the pandemic S Democrats on a coronavirus- is onceagain surging. A1 PRES relief package, further closing TheCommission on Pres- the gapbetween the parties in TED idential Debates scrapped CIA the on-again, off-again effort the planned matchup next SO to passnew aid forhouseholds AS week between Trump and T/ and businesses beforethe Biden afterthe president election. said he wouldn’t partici- HERBER pateinavirtual debate. A7 ALD By Kristina Peterson, Barr has told top Re- GER Kate Davidson SECOND BLOW: Danielle Fontenot raN with her son, Hunter, to a relative’s house in Lake Charles on Friday as Delta buf- publicans that the results and Andrew Duehren feted southwest Louisiana, which is still recovering from the ravages of Category 4 Hurricane Laura six weeks ago.
    [Show full text]
  • The Pandemic's First Major Research Scandal Erupts Kelly Servick and Martin Enserink
    Corrected 4 June 2020. See full text. A hydroxychloroquine study is being audited. statement, Surgisphere defended the integ- rity of its research and said it was pursu- ing “an independent academic audit” of its results in The Lancet. The journal and non- Surgisphere authors also said data reviews were underway. The episode has left leaders of halted hy- droxycholoroquine trials weighing whether to restart. “The problem is, we are left with all the damage that has been done,” says White, a co-investigator on a halted trial for COVID-19 prevention. It will now be hard to recruit people to key studies, he says. “The whole world thinks now that these drugs are poisonous.” Desai co-authored the Lancet paper with cardiologist Mandeep Mehra of Harvard University’s Brigham and Women’s Hospi- tal (BWH), cardiologist Frank Ruschitzka of Downloaded from University Hospital Zürich, and cardiac sur- geon Amit Patel, who listed affiliations with COVID 19 the University of Utah and HCA Research Institute in Nashville, Tennessee. (Mehra and Patel referred inquiries to BWH. Ruschitzka The pandemic’s first major did not respond to requests for comments.) http://science.sciencemag.org/ The authors describe an analysis of electronic health record data from patients already research scandal erupts treated for COVID-19 at 671 hospitals on six continents—nearly 15,000 people prescribed Critics question patient data used to challenge malaria drugs chloroquine or hydroxychloroquine, alone or in combination with an antibiotic, and a By Kelly Servick and Martin Enserink White, a malaria researcher at Mahidol Uni- control group of 81,000 other patients.
    [Show full text]
  • COVID-19 Research Scandal: Unwanted Diversion During Pandemic 6 June 2020, by Issam Ahmed
    COVID-19 research scandal: Unwanted diversion during pandemic 6 June 2020, by Issam Ahmed death. Its withdrawal is seen as a boost to backers of the decades-old anti-malarial drug, who include US President Donald Trump and his Brazilian counterpart Jair Bolsonaro. "It's very politicized—there is a group, probably not particularly small, who have learned to mistrust science and scientists, and this just feeds into that narrative," Gabe Kelen, a professor of emergency medicine at Johns Hopkins University, told AFP. This is despite the fact that even without The Lancet paper, evidence has been building against A pharmacy tech holds a tablet of hydroxychloroquine hydroxychloroquine's use against COVID-19. On Friday, results from a fourth randomized controlled trial—carefully designed human The first research scandal of the coronavirus experiments considered the most robust form of pandemic has created unnecessary distraction clinical investigation—showed it had no impact around the politically divisive drug against the virus. hydroxychloroquine, scientists say, as questions swirl around the tiny health care company at the Mystery company center of the affair. The Lancet, which first published in 1823, is one of On Thursday, most of the authors of major studies the world's most trusted medical journals. that appeared in The Lancet and the New England Journal of Medicine (NEJM) retracted their work As a result, the hydroxychloroquine paper had an and issued apologies, saying they could no longer outsized impact: the World Health Organization, vouch for their data after the firm that supplied Britain and France all suspended ongoing clinical it—Chicago-based Surgisphere—refused to be trials.
    [Show full text]
  • E Cacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
    Ecacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic Ahmed Elgazzar ( [email protected] ) Banha University Basma Hany Community Medicine Department, Faculty of Medicine, Benha University, Egypt. Shaimaa Abo Youssef Banha University Mohy Hafez Benha Faculty of medicine Hany Moussa Kafr Elsheikh University, Faculty of medicine, Chest department Abdelaziz eltaweel Benha University Article Keywords: Ivermectin, COVID-19, Hydroxychloroquine Posted Date: November 16th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-100956/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License EDITORIAL NOTE: Research Square withdrew this preprint on 14 July, 2021 due to an expression of concern communicated directly to our staff. These concerns are now under formal investigation. (note updated 19 July, 2021) Page 1/13 Abstract Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication ecacy "Ivermectin" plus standard care ((Azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000)) in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts in comparison to the Hydroxychloroquine plus standard treatment. Subject and methods: 600 subjects; 400 symptomatic
    [Show full text]
  • A Knee-Jerker During Pandemic? Praised As a Potential Miracle Cure, Hundreds of Trials Got Initiated Across the Globe for HCQ
    COVID-19 31 BIOSPECTRUM | JULY 2020 | www.biospectrumasia.com Controversial papers in NEJM and The Lancet A kNEE-JERkER DURING pandemic? Praised as a potential miracle cure, hundreds of trials got initiated across the globe for HCQ. Scientists started trying the drugs in low and high doses; alone or combined with other drugs in patients with mild or severe disease. But this hope recently got struck by a big blow when a study came along claiming that these antimalarial drugs not only look ineffective, but are downright deadly. he absence of an effective treatment against School, US; Frank Ruschitzka fromUniversity Heart the coronavirus infection has led clinicians to Center, University Hospital Zurich, Switzerland; and Tredirect drugs that are known to be effective Dr Amit N Patel from Department of Biomedical for other medical conditions to the treatment of Engineering, University of Utah, Salt Lake City, US. COVID-19. Key among these repurposed therapeutic They used hospital records procured by an agents are the antimalarial drug chloroquine (CQ) American healthcare analytics company Surgisphere and its analogue hydroxychloroquine (HCQ), which Corporation, established in 2008 by an Indian is used for the treatment of autoimmune diseases, Sapan Desai, for their study. According to their such as systemic lupus erythematosus and findings, COVID-19 patients taking CQ or rheumatoid arthritis. HCQ were associated with an increase in Praised as a potential miracle the risk of ventricular arrhythmias and cure,hundreds of trials got initiated a greater hazard for in-hospital death across the globe for HCQ. Scientists with COVID-19. The study concluded started trying the drugs in low and that these drug regimens should high doses; alone or combined with not be used outside of clinical other drugs in patients with mild or trials and urgent confirmation severe disease.
    [Show full text]
  • Lancet, NEJM Retract Studies on HCQ
    Politicized Science: Lancet, NEJM retract studies on HCQ By Celia Farber - June 6, 2020 Medical Scandal of the Decade Erupts as Lancet and NEJM Both Retract Studies Finding Hydroxychloriquine Deadly and Ineffective At 3:15 pm on June 4, I got a text from my friend Josh in Los Angeles that stopped me in my tracks. The text read: “The fake Lancet Hydroxychloroquine study has been retracted.” I called Josh. “Are you serious?” He’d already texted me the retraction, but still I could barely believe it. Turns out NEJM had also retracted. This was huge. Dr. James Todaro, who runs a website, MedicineUncensored, which publishes the results of HCQ studies, tweeted yesterday: “This is exploding into one of the most twisted and unbelievable medical scandals of the decade.” Todaro (and social media “sleuths”) were the first to expose the truth, in late May on his site: UncoverDC reached out to Dr. Todaro to confirm that he was the first to expose the scandal. “Yes that is correct,” he wrote. “My report was the first to make a detailed investigation into Surgisphere. [The data company.] My report came out May 29.” 6 days later, on June 4, the two most prominent medical journals in the world had both retracted the HCQ papers; Two ships hitting the same iceberg. It is very rare for a major medical journal to retract a paper, especially one that supports an entire orthodoxy. This paper pinned together the very trinity of Covid-19’s economic and political faith: By taking down HCQ, as “dangerous,” it took direct aim also at President Trump.
    [Show full text]
  • Usefulness of Ivermectin in COVID-19 Illness
    Usefulness of Ivermectin in COVID-19 Illness Amit N. Patel MD, MS1,2; Sapan S. Desai MD PhD MBA3; David W. Grainger PhD1; Mandeep R. Mehra,MD, MSc4 1Department of Bioengineering, University of Utah, Salt Lake City, UT; 2HCA Research Institute, Florida; 3Surgisphere Corporation, Chicago, Illinois; 4Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA; Corresponding Author: Amit N. Patel [email protected] or Mandeep R. Mehra, 75 Francis Street, Boston, MA 02115 or at [email protected], Fax: 617-264-5265; Tel: 617-732-8534; Twitter Handle: @MRMehraMD Key Points: Question: Does the antimicrobial drug, Ivermectin influence outcome in COVID-19 illness? Findings: This observational propensity-matched case-controlled study in 1,408 patients (704 that received ivermectin and 704 that did not) demonstrated an association of ivermectin use with lower in-hospital mortality 1.4% versus 8.5% (Ivermectin versus no ivermectin; HR 0.20 CI 95% 0.11-0.37, p<0.0001). Meaning: Ivermectin is associated with a potential survival benefit in COVID-19 and this should be investigated urgently in randomized controlled trials. Abstract: Importance: There is no established anti-viral therapy for treating COVID-19 illness. Objective: To study the usefulness of Ivermectin, an antimicrobial therapy, in COVID-19 outcomes. Design: An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with COVID-19 between January 1, 2020 and March 31, 2020. Setting: An international multi- institutional deidentified healthcare outcomes database. Participants: Hospitalized patients diagnosed with COVID-19 determined by presence of a positive laboratory finding confirming SARS-CoV-2 infection.
    [Show full text]
  • Twitter Activity About Treatments During the COVID-19 Pandemic: Case Studies of Remdesivir, Hydroxychloroquine, and Convalescent Plasma
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.18.20134668; this version posted June 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Title: Twitter activity about treatments during the COVID-19 pandemic: case studies of remdesivir, hydroxychloroquine, and convalescent plasma. Authors: 1) Tymor Hamamsy. Center for Data Science, New York University. New York, NY. USA. 2) Richard Bonneau. Department of Biology and Computer Science, New York University. New York, NY. USA. Corresponding author: Name: Tymor Hamamsy Email: [email protected] Abstract Since the COVID-19 pandemic started, the public has been eager for news about promising treatments, and social media has played a large role in information dissemination. In this paper, our objectives are to characterize the public discussion of treatments on Twitter, and demonstrate the utility of these discussions for public health surveillance. We pulled tweets related to three promising COVID-19 treatments (hydroxychloroquine, remdevisir and convalescent plasma), between the dates of February 28th and May 22nd using the Twitter public API. We characterize treatment tweet trends over this time period. Most major tweet/retweet/sentiment trends correlated to public announcement made by the white house and/or to new clinical trial evidence about treatments. Most of the websites people shared in treatment-related tweets were non- scientific media sources that leaned conservative. Hydroxychloroquine was the most discussed treatment on Twitter, and over 10% of hydroxychloroquine tweets mentioned an adverse drug reaction.
    [Show full text]